Programme

This years IPSCC will start on the 24th of June (12pm) and will end on the 26th of June (1pm). The programme will include oral and poster presentations from the student attendees, three presentations from high-profile keynote speakers. In addition, there will be career workshops focusing on a variety of scientific careers within and beyond academia. During the social events in the evening you will also have the opportunity to network with your fellow PhD peers and take part in a traditional Scottish Ceilidh dance.

We will publish the full programme closer to the start of the event.

We are excited to announce the following keynote speakers:

Ilaria MalanchiFrancis Crick Institute, London, UK

Ilaria Malanchi

Ilaria Malanchi obtained her Master degree at the University of Siena after two years spent at the research centre of Chiron Vaccine, (later Novartis Vaccine and now GSK, Siena, Italy). She obtained her PhD from Heidelberg University (Germany) working in the laboratory of Dr Tommasino at the DKFZ. As Dr Tommasino moved his laboratory to France in 2003, she spent one year at the IARC (WHO, Lyon, France). Her long-standing interest in the complex cancer cellular interaction in vivo began when she moved to the newly opened Joerg Huelsken lab at the ISREC, Lausanne, Switzerland, (now part of the Federal Swiss University (EPFL)), to start her postdoc in 2004. During these Postdoc years she began to investigate the importance of tumour microenvironment during metastatic progression. Building on this expertise in mouse tumour models, Ilaria set up her laboratory at the Cancer Research UK London Research Institute in 2011 (now part of the Francis Crick Institute) and has since focused the scope of investigation on the interaction between cancer cells and the surrounding tissue during tumorigenesis and metastatic progression. Ilaria was awarded tenure and promoted to Senior Group Leader at the Francis Crick Institute in 2018.

Gerard EvanUniversity of Cambridge, UK

Gerard Evan

Professor Gerard Evan received his BA in Biochemistry from the University of Oxford and his Ph.D. in Molecular Immunology from the MRC Laboratory of Molecular Biology at the University of Cambridge. He was then a postdoctoral fellow in the laboratory of J. Michael Bishop at the University of California, San Francisco (UCSF), returning to the UK to become an Assistant Member of the Cambridge Branch of the Ludwig Institute for Cancer Research and a Research Fellow of Downing College, Cambridge. In 1988 he joined the Imperial Cancer Research Fund (ICRF) Laboratories in London as a Senior Scientist and then Principal Scientist from 1990-1999. In 1996 he was awarded the Royal Society’s Napier Chair of Cancer Research. In 1999, he was appointed Distinguished Professor of Cancer Biology at the University of California, San Francisco and in 2009 moved back to the UK to take up the Sir William Dunn chair of Biochemistry in the University of Cambridge. Professor Evan focuses on the role of oncogenes, the genes that drive the development of cancer. His principal interest is the transcription factor Myc, which is aberrantly regulated in almost all human cancers and helps tumours grow, spread and develop a blood supply. Consequently, many think that drugs targeting Myc could be a good way to treat cancer. However, Myc also serves many different roles in healthy cells as well as in cancer cells. Evan and his team are working to understand exactly how Myc works within the body, both in healthy tissue and in several types of cancer, including lung and pancreatic adenocarcinomas. His group is also using innovative ways of testing how effective inhibiting Myc would actually be in treating cancers, as well as searching for other genes that work with Myc, since they could also be good targets for future cancer treatments. Professor Evan is a member of EMBO, a Fellow of the UK Academy of Medical Sciences, the European Academy of Cancer Sciences, and the Royal Society.

Eyal GottliebRappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel

Eyal Gottlieb

Dr Eyal Gottlieb received a BSc in Agricultural Sciences from the Hebrew University of Jerusalem in 1990, and an MSc (1993) and a PhD (1999) in Molecular Cell Biology from the Weizmann Institute of Science where he studied the role of the tumour suppressor p53 in apoptosis. In 1998 Dr Gottlieb moved to the University of Chicago as an EMBO fellow to study the metabolic regulation of cell death and in 2000 he became a Leukemia and Lymphoma Society Special Fellow at the University of Pennsylvania. Since 2003, he was a Research Group Leader at the Cancer Research UK, Beatson Institute, in Glasgow, UK where he worked on cancer metabolism. Dr Gottlieb studies the metabolic adaptations that support tumour growth under metabolic stress. Specifically, he explores vulnerabilities induced by the loss of the metabolic tumour suppressors fumarate hydratase (FH) and succinate dehydrogenase (SDH). Among Dr Gottlieb’s key accomplishments is the identification of onco-metabolic signalling cascades mediated by TCA cycle metabolites, the elucidation of metabolic adaptations to FH or SDH loss, the discovery that L-serine is a glycolysis regulator and, the discovery that under metabolic stress, acetate is essential for tumour growth. In 2009 Dr Gottlieb was appointed a Professor of Molecular Cell Biology at the University of Glasgow and from 2013 was the Director of the Beatson’s Cancer Metabolism Research Unit. From January 2016, Dr Gottlieb is the Director of the Laura and Isaac Perlmutter Metabolomics Center at the Technion Integrative Cancer Center (TICC).